Pair Name	Zeylenone, Cisplatin
Disease Info	[ICD-11: 2B51]	Osteosarcoma		Investigative
Biological Phenomena	Induction-->DNA damage
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Cleavage	CASP8	hsa841
	Down-regulation	Expression	CDK2	hsa1017
	Up-regulation	Expression	CDKN1A	hsa1026
	Up-regulation	Expression	CHEK1	hsa1111
	Down-regulation	Expression	FANCD2	hsa2177
	Down-regulation	Expression	FANCI	hsa55215
	Down-regulation	Phosphorylation	GSK3B	hsa2932
	Up-regulation	Expression	H2AX	hsa3014
	Down-regulation	Expression	HSP90AA1	hsa3320
	Up-regulation	Expression	MLKL	hsa197259
	Up-regulation	Expression	RB1	hsa5925
	Up-regulation	Expression	RIPK1	hsa8737
	Up-regulation	Expression	RIPK3	hsa11035
	Up-regulation	Expression	TP53	hsa7157
In Vitro Model	CCRF S-180 II	Mouse fibrosarcoma	Mus musculus (Mouse)	CVCL_2874
	HOS	Osteosarcoma	Homo sapiens (Human)	CVCL_0312
	U2OS	Osteosarcoma	Homo sapiens (Human)	CVCL_0042
In Vivo Model	5×10⁵ S180 cells wereinjected into the peritoneal cavity of the mice and proliferated to pro-duce ascites.
Result	Zeylenone synergizes with cisplatin in osteosarcoma by enhancing DNA damage, apoptosis, and necrosis via the Hsp90/AKT/GSK3β and Fanconi anaemia pathway